Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) research SEATTLE, May 20, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (Atossa or the Company), a...